West Pharmaceutical Services, Inc. (NYSE:WST) Receives $368.08 Average Target Price from Analysts

West Pharmaceutical Services, Inc. (NYSE:WST) has been assigned an average recommendation of “Buy” from the fifteen research firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $368.0769.

Several research analysts have weighed in on WST shares. Evercore reiterated an “outperform” rating and set a $425.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Friday, July 24th. KeyCorp raised their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Finally, Morgan Stanley boosted their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th.

Institutional Investors Weigh In On West Pharmaceutical Services

Several institutional investors have recently made changes to their positions in WST. BlackRock Inc. bought a new position in West Pharmaceutical Services during the 2nd quarter worth $2,387,990,000. State Street Corp lifted its position in shares of West Pharmaceutical Services by 2.1% during the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after acquiring an additional 68,330 shares during the period. Artisan Partners Limited Partnership grew its holdings in shares of West Pharmaceutical Services by 2.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock worth $784,259,000 after purchasing an additional 79,481 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth $733,733,000. Finally, Geode Capital Management LLC increased its position in shares of West Pharmaceutical Services by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 1,869,086 shares of the medical instruments supplier’s stock worth $512,250,000 after purchasing an additional 11,962 shares during the period. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Trading Up 1.4%

Shares of NYSE:WST opened at $353.61 on Thursday. West Pharmaceutical Services has a 12-month low of $223.83 and a 12-month high of $386.00. The business has a 50 day moving average of $342.97 and a 200-day moving average of $292.25. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The stock has a market cap of $24.89 billion, a PE ratio of 45.28, a P/E/G ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities research analysts forecast that West Pharmaceutical Services will post 8.94 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.